The Phase III IMpower133 study has met its overall survival and progression-free survival co-primary endpoints.
Browsing: progression-free survival
AstraZeneca and MedImmune have announced results of their Phase III PACIFIC trial.
Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review
Systemic review and meta-analysis to assess the efficacy of allogenic hematopoietic cell transplantation in Mantle cell lymphoma when using myeloablative conditioning or reduced-intensity conditioning regimes.
Niraparib, a highly selective PARP inhibitor, has been demonstrated to significantly improve progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA-mutation status.
ASCO15: Ipilimumab/nivolumab combination treatment shows significant improvement in response rates for advanced melanoma
The results of a Phase III randomized trial presented at ASCO 2015 have indicated that the use of nivolumab alone or in combination with ipilimumab for the treatment of melanoma is more effective than the use of ipilimumab alone.
The latest results from a Phase II prospective, multicenter study published recently in The New England Journal of Medicine indicate that ibrutinib may be successful in controlling Waldenström’s macroglobulinemia.
A Phase II clinical trial has found that sunitinib shows significant cancer-fighting activity in patients with advanced differentiated thyroid cancer.
Stereotactic body radiation therapy plus chemotherapy improves survival among stage IV lung cancer patients
Survival more than doubled for certain stage IV lung cancer patients in a clinical trial that combined stereotactic body radiation therapy (SBRT) with an erlotinib chemotherapy regimen.
Platinum-based combination well tolerated and clinically active in metastatic triple-negative breast cancer
Rutgers Cancer Institute of New Jersey (NJ, USA) investigators recently presented data from a Phase II clinical trial demonstrating that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen for metastatic triple-negative breast cancer.